SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. [electronic resource]
Producer: 20190510Description: 961-967 p. digitalISSN:- 1546-170X
- Animals
- Carcinoma, Non-Small-Cell Lung -- genetics
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Cellular Senescence -- drug effects
- Guanosine Triphosphate -- metabolism
- Humans
- Lung Neoplasms -- genetics
- Mice
- Mitogen-Activated Protein Kinase Kinases -- antagonists & inhibitors
- Mutation -- genetics
- Protein Kinase Inhibitors -- pharmacology
- Protein Tyrosine Phosphatase, Non-Receptor Type 11 -- metabolism
- Proto-Oncogene Proteins p21(ras) -- genetics
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.